SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 224 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $937 | -13.0% | 33,991 | -5.2% | 0.01% | -7.7% |
| Q2 2023 | $1,077 | -19.7% | 35,844 | -3.2% | 0.01% | -18.8% |
| Q1 2023 | $1,341 | -0.1% | 37,018 | -1.7% | 0.02% | -5.9% |
| Q4 2022 | $1,342 | -99.9% | 37,642 | +1.5% | 0.02% | 0.0% |
| Q3 2022 | $1,254,000 | +7.4% | 37,070 | -8.2% | 0.02% | +21.4% |
| Q2 2022 | $1,168,000 | -2.3% | 40,401 | +9.2% | 0.01% | +7.7% |
| Q1 2022 | $1,195,000 | +8.8% | 36,996 | -1.8% | 0.01% | +18.2% |
| Q4 2021 | $1,098,000 | +6.2% | 37,656 | -2.9% | 0.01% | +10.0% |
| Q3 2021 | $1,034,000 | -8.4% | 38,771 | +5.7% | 0.01% | -9.1% |
| Q2 2021 | $1,129,000 | +20.5% | 36,694 | +2.4% | 0.01% | +10.0% |
| Q1 2021 | $937,000 | -9.1% | 35,824 | -12.6% | 0.01% | -16.7% |
| Q4 2020 | $1,031,000 | +0.5% | 41,004 | -16.8% | 0.01% | -7.7% |
| Q3 2020 | $1,026,000 | -12.8% | 49,272 | -0.6% | 0.01% | -13.3% |
| Q2 2020 | $1,177,000 | +40.6% | 49,562 | +6.5% | 0.02% | +15.4% |
| Q1 2020 | $837,000 | -10.9% | 46,552 | +17.5% | 0.01% | +8.3% |
| Q4 2019 | $939,000 | -15.2% | 39,617 | -1.7% | 0.01% | -20.0% |
| Q3 2019 | $1,107,000 | +87.6% | 40,292 | +126.0% | 0.02% | +50.0% |
| Q2 2019 | $590,000 | -4.4% | 17,831 | +1.1% | 0.01% | -9.1% |
| Q1 2019 | $617,000 | +6.2% | 17,636 | +0.7% | 0.01% | 0.0% |
| Q4 2018 | $581,000 | -32.3% | 17,506 | +2.6% | 0.01% | -21.4% |
| Q3 2018 | $858,000 | -15.3% | 17,059 | +0.7% | 0.01% | -22.2% |
| Q2 2018 | $1,013,000 | +32.9% | 16,939 | +1.8% | 0.02% | +12.5% |
| Q1 2018 | $762,000 | +87.7% | 16,639 | +63.0% | 0.02% | +60.0% |
| Q4 2017 | $406,000 | +2.0% | 10,209 | +2.4% | 0.01% | -50.0% |
| Q3 2017 | $398,000 | -6.8% | 9,969 | +0.4% | 0.02% | -31.0% |
| Q2 2017 | $427,000 | +146.8% | 9,929 | +79.5% | 0.03% | +123.1% |
| Q1 2017 | $173,000 | +28.1% | 5,530 | +3.2% | 0.01% | 0.0% |
| Q4 2016 | $135,000 | – | 5,360 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |